

Agnieszka Dansonka-Mieszkowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3584314/publications.pdf>

Version: 2024-02-01

52
papers

3,657
citations

201674

27
h-index

175258

52
g-index

52
all docs

52
docs citations

52
times ranked

7051
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
3	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
4	A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. <i>Laboratory Investigation</i> , 2004, 84, 874-883.	3.7	292
5	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
6	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
7	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
8	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
9	Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3' End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course. <i>Modern Pathology</i> , 2003, 16, 1257-1264.	5.5	104
10	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
11	A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. <i>BMC Medical Genetics</i> , 2010, 11, 20.	2.1	96
12	Ovarian small cell carcinoma of hypercalcemic type – evidence of germline origin and smarca4 gene inactivation. a pilot study. <i>Polish Journal of Pathology</i> , 2013, 4, 238-246.	0.3	85
13	PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. <i>Cancer Biology and Therapy</i> , 2009, 8, 21-26.	3.4	81
14	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
15	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
16	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
17	Evaluation of NF2 and NF1 Tumor Suppressor Genes in Distinctive Gastrointestinal Nerve Sheath Tumors Traditionally Diagnosed as Benign Schwannomas: A Study of 20 Cases. <i>Laboratory Investigation</i> , 2003, 83, 1361-1371.	3.7	65
18	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63

#	ARTICLE	IF	CITATIONS
19	The putative oncogene, <i>CRNDE</i> is a negative prognostic factor in ovarian cancer patients. <i>Oncotarget</i> , 2015, 6, 43897-43910.	1.8	51
20	Risk of Ovarian Cancer and the NF- κ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.	0.9	48
21	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
22	The Novel Gene <i>CRNDE</i> Encodes a Nuclear Peptide (<i>CRNDEP</i>) Which Is Overexpressed in Highly Proliferating Tissues. <i>PLoS ONE</i> , 2015, 10, e0127475.	2.5	40
23	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015, 24, 3595-3607.	2.9	40
24	Evidence of a genetic link between endometriosis and ovarian cancer. <i>Fertility and Sterility</i> , 2016, 105, 35-43.e10.	1.0	37
25	Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. <i>Laboratory Investigation</i> , 2005, 85, 237-247.	3.7	34
26	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	7.0	33
27	Germline <i>SMARCA4</i> mutations in patients with ovarian small cell carcinoma of hypercalcemic type. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 32.	2.7	31
28	Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1239-1252.	2.5	30
29	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
30	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
31	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
32	Enrichment of putative <i>PAX8</i> target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	6.4	23
33	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
34	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	3.4	21
35	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	2.5	20
36	Clinical importance of <i>FANCD2</i> , <i>BRIP1</i> , <i>BRCA1</i> , <i>BRCA2</i> and <i>FANCF</i> expression in ovarian carcinomas. <i>Cancer Biology and Therapy</i> , 2019, 20, 843-854.	3.4	20

#	ARTICLE	IF	CITATIONS
37	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
38	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
39	The significance of c.690G>T polymorphism (rs34529039) and expression of the <i>CEBPA</i> gene in ovarian cancer outcome. <i>Oncotarget</i> , 2016, 7, 67412-67424.	1.8	17
40	Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	3.3	16
41	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
42	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
43	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	1.9	15
44	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
45	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
46	p19 ^{INK4d} mRNA and protein expression as new prognostic factors in ovarian cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 973-981.	3.4	11
47	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
48	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5
49	The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas – an important diagnostic pitfall. <i>Pathology Research and Practice</i> , 2021, 225, 153555.	2.3	4
50	Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 17735-17755.	1.8	4
51	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3
52	Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation – evaluation of in vivo sensitivity to imatinib. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 208-213.	0.5	1